目的 探讨亮菌甲素联合注射用头孢唑林钠治疗慢性胆囊炎急性发作的临床疗效。方法 回顾性分析2020年6月—2022年12月在焦作市人民医院治疗的86例慢性胆囊炎急性发作患者临床资料。根据用药种类的不同分为对照组和治疗组，每组各43例。对照组患者静脉滴注注射用头孢唑林钠，2.0 g加入生理盐水100 mL，1次/12 h；在此基础上，治疗组静脉滴注注射用亮菌甲素，5.0 mg加入生理盐水100 mL，1次/24 h。两组患者均经10 d治疗。观察两组患者临床疗效，比较治疗前后两组患者症状改善时间，血清C反应蛋白（CRP）、胆囊收缩素（CCK）、白细胞介素-6（IL-6）、核因子-κB（NF-κB）、肿瘤坏死因子-α（TNF-α）、天门冬酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）和总胆汁酸（TBA）水平。结果 治疗后，治疗组总有效率（97.96%）明显高于对照组（83.67%，P＜0.05）。治疗后，治疗组右上腹疼痛、恶心呕吐、口苦、腹胀改善时间上均早于对照组（P＜0.05）。治疗后，两组患者血清CRP、CCK、IL-6、NF-κB、TNF-α、AST、ALT和TBA水平均明显下降（P＜0.05），且治疗组这些血清学指标明显低于对照组（P＜0.05）。结论 亮菌甲素联合注射用头孢唑林钠治疗慢性胆囊炎急性发作可促进临床症状改善，降低肝损害，减轻机体炎症反应。

Objective Exploring the clinical efficacy of armillarisini anatricome combined with cefazolin sodium in treatment of acute exacerbation of chronic cholecystitis. Methods The clinical data of patients (86 cases) with acute exacerbation of chronic cholecystitis in Jiaozuo People’s Hospital from June 2020 to December 2022 were analyzed retrospectively. They were divided into control and treatment group, and each group had 43 cases based on different treatments. Patients in the control group were iv administered with Cefazolin Sodium for injection, 2 g added into normal saline 100 mL, once every 12 h. Patients in the treatment group were iv administered with Armillarisini Anatricome for injection on the basis of the control group, 5 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the levels of serum CRP, CCK, IL-6, NF-κB, TNF-α, AST, ALT, and TBA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.96%) was significantly higher than that of the control group (83.67%, P < 0.05). After treatment, the improvement time of right upper abdominal pain, nausea and vomiting, bitterness and abdominal distension in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the serum levels of CRP, CCK, IL-6, NF-κB, TNF-α, AST, ALT, and TBA were significantly decreased in two groups (P < 0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The combination of armillarisini anatricome and cefazolin sodium in treatment of acute exacerbation of chronic cholecystitis can promote the improvement of clinical symptoms, reduce liver damage and reduce inflammatory reaction.

R975